Medtronic Medical Device Companies Analysis

Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.

Additional Information

Founded in 1949, Minnesota, US-based Medtronic has grown to become a leading developer and manufacturer of medical devices designed to diagnose, prevent and monitor chronic conditions. Beginning with the development of the heart pacemaker in the 1950s, the company has assembled a broad and diverse portfolio of progressive technology expertise both through internal development of core technologies and acquisitions.

Medtronic’s primary products include those used for the treatment of cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose and throat conditions. The company operates under two principal business segments:

the Cardiac and Vascular Group (composed on the Cardiac Rhythm Disease Management (CRDM), CardioVascular and Physio-Control businesses), whose product portfolio includes pacemakers, implantable defibrillators, leads and delivery systems, ablation products, electrophysiology catheters, products for the treatment of atrial fibrillation (AF), information systems for the management of patients with CRDM devices, coronary and peripheral stents and related delivery systems, therapies for uncontrolled hypertension, endovascular stent graft systems, heart valve replacement technologies, tissue ablation systems, open heart and coronary bypass grafting surgical products, external defibrillators including manual defibrillator/monitors used by hospitals and emergency response personnel, and automated external defibrillators used in commercial and public settings for the treatment of cardiac arrest.

In November 2011, Medtronic reached a definitive agreement to sell its Physio-Control business, which offers a portfolio of external defibrillation and emergency response systems, data management solutions and support services, to the global private investment firm, Bain Capital. Since Medtronic and Physio-Control’s core businesses and customers are significantly different, both parties believe that Physio-Control will be able to move more quickly, be more competitive and have more direct focus on its customers as a separate entity.

the Restorative Therapies Group (composed of the Spinal, Neuromodulation, Diabetes and Surgical Technologies businesses), which offers products for various areas of the spine, bone graft substitutes, biologic products, implantable neurostimulation therapies and drug-delivery devices for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder (OCD), overactive bladder, urinary retention, and gastroparesis; external insulin pumps; subcutaneous continuous glucose monitoring (CGM) systems; and products to treat conditions of the ear, nose and throat (ENT). Additionally, this group manufactures and sells primarily image-guided surgery and intra-operative imaging systems. Medtronic conducts its business in more than 120 countries worldwide. In fiscal year 2011 (ended April 2011), the company generated sales of US$15.93 billion and employed approximately 45,000 people worldwide. In the six months to 28th October 2011, the company reported sales of US$8,181 million.

This company report provides

Overview`
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Products
Core product areas, key brands, product approvals and launches Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded

Mergers, Acquisitions, Minority Investments and Divestments

Litigation

Key Corporate Events